Pfizer and Eisai's Alzheimer's disease drug Aricept (donepezil) maycause urinary incontinence in a small number of patients, according to a letter in The Lancet (August 12). Japanese neurologists report in the letter that the side effect seems more likely to occur at higher doses (eg 5mg) and is reversible. They recommend that if a case of incontinence is suspected to be linked to the drug, using a lower dose, or concomitant use of a peripherally-acting cholinergic antagonist, might be helpful.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze